Skip to content

Efficacy and safety of Haima scorpion pill in the treatment of degenerative lumbar spinal stenosis

Research and development of TCM innovative drugs based on TCM prescription (hospital preparation)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000794
Enrollment
Unknown
Registered
2024-12-11
Start date
2024-12-31
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Degenerative lumbar spinal stenosis

Interventions

Experimental group:Scorpion pills of seahorse
Control group:Dan Lu Tong Du tablet

Sponsors

The First Hospital of Hunan University of traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1) Meet the diagnostic criteria of DLSS; 2)40 years old =65 years old male or female; 3) VAS>4 scores before enrollment; 4) The patient agrees to cooperate with the treatment follow-up and obtains the informed consent signed by the patient; If the patient is receiving or has recently received another treatment regimen a washout period of at least 1 week is required.

Exclusion criteria

Exclusion criteria: 1) For those who are allergic to any component of Danlutongdu Pill or Haima Quanscorpion pill to avoid interference of allergic reaction on experimental results and serious adverse consequences to patients; 2)Patients with severe heart lung liver kidney and other important organ dysfunction may be metabolic and safe for drugs.Sex evaluation has influence and may interfere with the evaluation of the efficacy of experimental drugs. 3) Pregnant or lactating women may have unknown adverse effects on the fetus or baby; 4) Spinal infection tumor tuberculosis traumatic fracture ankylosing spondylitis etc. 5) Patients with surgical indications or requirements for surgical treatment and those who have recently received other specific treatments related to the study disease and have not undergone sufficient washout period; 6) Patients with mental illness or cognitive impairment who cannot cooperate with treatment and follow-up may affect the accuracy of experimental results; 7)The presence of spinal cord intermittent claudication or vascular intermittent claudication; 8)Those who do not meet the age range of inclusion criteria their physical function and response to drugs may be significantly different from the target population.

Design outcomes

Primary

MeasureTime frame
Oswestry Disability Index;

Secondary

MeasureTime frame
VAS Score;Degree of intermittent claudication;Security indicators;JOA Score;Frequency of painful spasms and degree of chills in lower limbs;

Countries

China

Contacts

Public ContactShaofeng Yang

The First Hospital of Hunan University of traditional Chinese Medicine

575996487@qq.com+86 13873148670

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026